title: New Management Strategies in Heart Failure.
abstract: Despite >100 clinical trials, only 2 new drugs had been approved by the US Food and Drug Administration for the treatment of chronic heart failure in more than a decade: the aldosterone antagonist eplerenone in 2003 and a fixed dose combination of hydralazine-isosorbide dinitrate in 2005. In contrast, 2015 has witnessed the Food and Drug Administration approval of 2 new drugs, both for the treatment of chronic heart failure with reduced ejection fraction: ivabradine and another combination drug, sacubitril/valsartan or LCZ696. Seemingly overnight, a range of therapeutic possibilities, evoking new physiological mechanisms, promise great hope for a disease that often carries a prognosis worse than many forms of cancer. Importantly, the newly available therapies represent a culmination of basic and translational research that actually spans many decades. This review will summarize newer drugs currently being used in the treatment of heart failure, as well as newer strategies increasingly explored for their utility during the stages of the heart failure syndrome.
authors: From the Cardiovascular Division, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.
authors: Anjali Tiku
authors: AT
authors: Owens
authors: From the Cardiovascular Division, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.
authors: Susan C
authors: SC
authors: Brozena
authors: From the Cardiovascular Division, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia. jessupm@uphs.upenn.edu.
authors: Mariell
authors: M
authors: Jessup
mesh_terms: D000818:Animals; D058406:Cardiac Resynchronization Therapy / Q000009:adverse effects; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D006333:Heart Failure / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D006353:Heart-Assist Devices / Q000009:adverse effects; D006801:Humans; D010641:Phenotype; D020127:Recovery of Function; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D004338:Drug Combinations
keywords: United States Food and Drug Administration; cardiomyopathies; drug combinations; heart failure; pharmacology